BioLife Solutions (BLFS) Earnings Analysis
BioLife Solutions (BLFS) next reports earnings on 2026-08-06, consensus EPS -0.02 USD. Last quarter (2026-05-07) it beat with EPS 0.04 USD vs 0.01 USD est (+300%). It has beaten estimates in 5/5 recent quarters (100%). Trailing P/E -144.21.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does BLFS next report earnings?
| Next earnings date | 2026-08-06 |
|---|---|
| Consensus EPS estimate | -0.02 USD |
| Revenue estimate | 0.03B |
BLFS earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-05-07 | 0.04 USD | 0.01 USD | +300% | Beat |
| 2026-02-26 | 0.04 USD | -0.02 USD | +300% | Beat |
| 2025-11-06 | 0.04 USD | 0.002 USD | +1900% | Beat |
| 2025-05-08 | 0.04 USD | -0.04857 USD | +182.4% | Beat |
| 2025-03-03 | -0.01 USD | -0.06 USD | +83.3% | Beat |
Beat rate: 5/5 (100%) over reported quarters with consensus data.
BLFS valuation and analyst view
| Trailing P/E | -144.21 |
|---|---|
| Trailing EPS | -0.2166 USD |
| Price / book | 4.06 |
| Dividend yield | 0.00% |
| Market cap | 1.53B |
| Analyst consensus | Buy (17 buy / 0 hold / 0 sell) |
| Avg price target | 31 USD |
Related research pages
Frequently asked questions
When is BioLife Solutions (BLFS)'s next earnings date?
BioLife Solutions is next scheduled to report on 2026-08-06, with a consensus EPS estimate of -0.02 USD and revenue estimate of 0.03B.
Did BLFS beat earnings last quarter?
In its 2026-05-07 report, BLFS posted EPS of 0.04 USD versus a 0.01 USD estimate — a beat of 300%.
What is BLFS's earnings track record?
Over the last 5 reported quarters with consensus data, BLFS beat estimates 5 times (100%).
What is BLFS's current P/E ratio and EPS?
BLFS trades at a trailing P/E of -144.21 on trailing EPS of -0.2165975464054465 USD.
What do analysts rate BLFS?
Analyst consensus is "Buy" across 17 ratings (0 strong buy, 17 buy, 0 hold, 0 sell, 0 strong sell). Average 12-month price target: 31 USD.